Production (Stage)
Xenon Pharmaceuticals Inc.
XENE
$29.75
-$0.74-2.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -251.45M | -234.33M | -213.39M | -199.06M | -188.60M |
| Total Depreciation and Amortization | 2.62M | 2.55M | 1.29M | 2.35M | 2.29M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.79M | 41.97M | 43.72M | 33.78M | 26.03M |
| Change in Net Operating Assets | -828.00K | 5.42M | 2.97M | 587.00K | -2.61M |
| Cash from Operations | -199.86M | -184.40M | -165.41M | -162.35M | -162.89M |
| Capital Expenditure | -2.93M | -3.08M | -2.37M | -2.98M | -3.60M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 248.64M | 171.08M | -167.91M | -115.40M | -197.60M |
| Cash from Investing | 245.71M | 168.01M | -170.28M | -118.38M | -201.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.28M | 12.13M | 324.01M | 353.52M | 353.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13.28M | 12.13M | 324.01M | 353.52M | 353.52M |
| Foreign Exchange rate Adjustments | -1.37M | -1.67M | -269.00K | -611.00K | -50.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 57.76M | -5.93M | -11.95M | 72.18M | -10.62M |